Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

Since the COVID-19 pandemic began, many potential therapeutics that target SARS-CoV-2
and/or human proteins to control viral infection have been investigated, with a few receiving …

Summary The coronavirus disease 2019 (COVID-19) pandemic continues worldwide with
many variants arising, some of which are variants of concern (VOCs). A recent VOC, omicron …

Background The ZF2001 vaccine, which contains a dimeric form of the receptor-binding
domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an …

The current pandemic of COVID-19 is fueled by more infectious emergent Omicron variants.
Ongoing concerns of emergent variants include possible recombinants, as genome …

Omicron Neutralization with a Longer Booster Interval In a study involving recipients of the
Chinese inactivated vaccines and the ZF2001 protein subunit vaccine, neutralizing antibody …

Background Due to the national dynamic zero-COVID strategy in China, there were no
persistent local transmissions of SARS-CoV-2 in Beijing before December, 2022. However …

Despite timely immunization programs, and efficacious vaccines conveying protection
against SARS-CoV-2 infection, breakthrough infections in vaccinated individuals have been …

The number of genetic variations in the SARS-CoV-2 genome has been increasing primarily
due to continuous viral mutations. Here, we report that the human APOBEC3A (A3A) cytidine …

Safe, efficacious, and deployable vaccines are urgently needed to control COVID-19 in the
large-scale vaccination campaigns. We report here the preclinical studies of an approved …